tert-butyl 4-({[6-(dibenzylamino)-5-nitropyrimidin-4-yl]amino}methyl)piperidine-1-carboxylate | 1351636-77-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-({[6-(dibenzylamino)-5-nitropyrimidin-4-yl]amino}methyl)piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-[[[6-(dibenzylamino)-5-nitropyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate
• CAS: 1351636-77-5
• 化学式: C₂₉H₃₆N₆O₄
• 分子量: 532.643
• InChiKey: YVKJIHNFIZKSLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• PURINONE COMPOUNDS AS KINASE INHIBITORS
  申请人：CHEN Wei

  公开号：US20130197014A1

  公开（公告）日：2013-08-01

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了与布鲁顿氏酪氨酸激酶（Btk）形成共价键的化合物。还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症（包括淋巴瘤）和炎症性疾病或症状。
• PURINONE DERIVATIVE
  申请人：Yamamoto Shingo

  公开号：US20130079327A1

  公开（公告）日：2013-03-28

  Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.

  由一般公式（I）表示的化合物（公式中的所有符号符合说明中的定义）是除了具有Btk选择性抑制活性外，还表现出优异的代谢稳定性，可以避免肝毒性或类似情况，从而可以为B细胞或肥大细胞参与的疾病提供安全的治疗药物。
• Purinone derivative
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10233185B2

  公开（公告）日：2019-03-19

  Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.

  通式（I）所代表的化合物（式中的所有符号均符合说明中的定义）除了具有 Btk 选择性抑制活性外，还具有极佳的代谢稳定性，可避免肝毒性或类似毒性，因此可为 B 细胞或肥大细胞参与的疾病提供安全的治疗剂。
• PURINONE DERIVATIVE AS BTK KINASE INHIBITOR
  申请人：ONO Pharmaceutical Co., Ltd.

  公开号：EP2578585B1

  公开（公告）日：2016-07-20
• US8501724B1
  申请人：——

  公开号：US8501724B1

  公开（公告）日：2013-08-06